论文部分内容阅读
目的:探讨生长激素(growth hormone,GH)在体外受精-胚胎移植(in vitro fertilization-em-bryo transfer,IVF-ET)治疗中对子宫内膜发育不良者子宫内膜及临床结局的影响。方法:IVF-ET患者共67例,均由于子宫内膜发育不良而致IVF-ET种植失败,再次行IVF-ET治疗时随机分为研究组(加用GH治疗,32例)和对照组(未使用GH治疗,35例),统计分析患者的临床结局。结果:患者Gn用量、平均获卵数、受精率、优质胚胎率组间无统计学差异(P>0.05);研究组子宫内膜厚度、形态及子宫内膜和内膜下血流均较对照组有明显改善(P<0.01);研究组的胚胎种植率(31.4%)及临床妊娠率(39.5%)明显高于对照组(15.7%和19.8%)(P<0.01),早期流产率明显减低(14.6%vs 21.4%)(P<0.01)。结论:对内膜发育不良的患者进行IVF-ET治疗时加用GH可能是通过改善子宫内膜对胚胎的容受性,从而提高胚胎种植率及临床妊娠率,降低早期流产率。
Objective: To investigate the effect of growth hormone (GH) on endometrial and clinical outcomes of endometrial dysplasia in in vitro fertilization-embryo transfer (IVF-ET). Methods: A total of 67 patients with IVF-ET were enrolled in this study. All of them were failed due to poor endometrial dysplasia. IVF-ET was randomly divided into study group (plus GH treatment, 32 cases) and control group GH without treatment, 35 cases), the clinical analysis of the clinical outcome. Results: There was no significant difference in the amount of Gn, the average number of oocytes retrieved, the rate of fertilization and the rate of high quality embryos (P> 0.05). The thickness, morphology, endometrial and subintimal blood flow of the study group were significantly higher than those of the control (P <0.01). The embryo implantation rate (31.4%) and clinical pregnancy rate (39.5%) in the study group were significantly higher than those in the control group (15.7% and 19.8%, P <0.01) Decrease (14.6% vs 21.4%) (P <0.01). Conclusion: Adding GH to IVF-ET in patients with endometrial dysplasia may improve embryo implantation rate and clinical pregnancy rate and improve early abortion rate by improving endometrial receptivity to embryos.